Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer

被引：36

作者：

Hata, Akito ^{[1
]}

Katakami, Nobuyuki ^{[1
]}

Nanjo, Shigeki ^{[1
]}

Okuda, Chiyuki ^{[1
]}

Kaji, Reiko ^{[1
]}

Masago, Katsuhiro ^{[1
]}

Fujita, Shiro ^{[1
]}

Yoshida, Hiroshi ^{[2
]}

Zama, Kota ^{[2
]}

Imai, Yukihiro ^{[3
]}

Hirata, Yukio ^{[1
]}

机构：

[1] Inst Biomed Res & Innovat Hosp, Div Integrated Oncol, Kobe, Hyogo, Japan

[2] GeneticLab Co Ltd, Dept Contract Res Clin Pathol, Sapporo, Hokkaido, Japan

[3] Gen Hosp, Kobe City Med Ctr, Dept Clin Pathol, Kobe, Hyogo, Japan

来源：

LUNG CANCER | 2017年 / 111卷

关键词：

Programmed death-ligand 1; T790M; Epidermal growth factor receptor mutation; Non-small cell lung cancer; Rebiopsy; GROWTH-FACTOR-RECEPTOR; RANDOMIZED CONTROLLED-TRIAL; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; IMMUNE ESCAPE; OPEN-LABEL; MUTATIONS; GEFITINIB; DOCETAXEL; THERAPY;

D O I：

10.1016/j.lungcan.2017.07.022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Differential biology and prognosis between T790M + and T790M- populations imply immunological differences also. Methods: We retrospectively analyzed programmed death-ligand 1 (PD-L1) expression and T790M status in rebiopsied samples of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). PD-Ll immunohistochemistry was performed using the SP142 antibody for tumour cell (TC) and tumour-infiltrating immune cell (IC) and the 28-8 antibody for TC. PD-Ll + was defined as TC or IC >= 1%. Results: We investigated 67 available rebiopsied histologic samples in 47 patients. Using the SP142, prevalence of PD-Ll any +, moderate +, and strong + in T790M+ vs. T790M- samples were 31% vs. 61%, 8% vs. 15%, and 0% vs. 2%, respectively, representing PD-Ll + prevalence of T790M + samples was significantly lower than that of T790M- (p = 0.0149). Prevalence of any TC + /IC + in T790M + vs. T790M- samples were TC: 31% vs. 51% (p = 0.0997) and IC: 8% vs. 27% (p = 0.0536), respectively. Using the 28-8, median percentage of PD-Ll + in T790M + samples was 1.9 (range, 0-27.2), whereas T790M- was 4.1 (range, 0-89.8) (p = 0.0801). Prevalence of PD-Ll + >= 1%, >= 5%, and >= 10% in T790M+ vs. T790M- samples were 77% vs. 83% (p = 0.5476), 31% vs. 49% (p = 0.1419), and 12% vs. 27% (p = 0.1213), respectively. In 9 of 11 patients receiving multiple re biopsies, T790M and/or PD-Li expression revealed temporal dynamism. Survival curves according to PD-Ll expression/T790M status suggested better prognosis in PD-L1-/T790M + population. Conclusions: T790M + status was correlated to lower PD-L1 expression. PD-Ll expression might have a prognostic value and interaction with T790M mutation in EGFR-mutant NSCLC.

引用

页码：182 / 189

页数：8

共 32 条

[1] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[2] Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].

Azuma, K. ;

Ota, K. ;

Kawahara, A. ;

Hattori, S. ;

Iwama, E. ;

Harada, T. ;

Matsumoto, K. ;

Takayama, K. ;

Takamori, S. ;

Kage, M. ;

Hoshino, T. ;

Nakanishi, Y. ;

Okamoto, I. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940

[3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[4] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[5] Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].

Chen, Nan ;

Fang, Wenfeng ;

Zhan, Jianhua ;

Hong, Shaodong ;

Tang, Yanna ;

Kang, Shiyang ;

Zhang, Yaxiong ;

He, Xiaobo ;

Zhou, Ting ;

Qin, Tao ;

Huang, Yan ;

Yi, Xianping ;

Zhang, Li .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923

[6] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[7] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[8] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis [J].

Gainor, Justin F. ;

Shaw, Alice T. ;

Sequist, Lecia V. ;

Fu, Xiujun ;

Azzoli, Christopher G. ;

Piotrowska, Zofia ;

Huynh, Tiffany G. ;

Zhao, Ling ;

Fulton, Linnea ;

Schultz, Katherine R. ;

Howe, Emily ;

Farago, Anna F. ;

Sullivan, Ryan J. ;

Stone, James R. ;

Digumarthy, Subba ;

Moran, Teresa ;

Hata, Aaron N. ;

Yagi, Yukako ;

Yeap, Beow Y. ;

Engelman, Jeffrey A. ;

Mino-Kenudson, Mari .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4585-4593

[9] Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI [J].

Hata, Akito ;

Katakami, Nobuyuki ;

Yoshioka, Hiroshige ;

Kaji, Reiko ;

Masago, Katsuhiro ;

Fujita, Shiro ;

Imai, Yukihiro ;

Nishiyama, Akihiro ;

Ishida, Tadashi ;

Nishimura, Yoshihiro ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (11) :1553-1559

[10] Rebiopsy of Non-Small Cell Lung Cancer Patients With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor [J].

Hata, Akito ;

Katakami, Nobuyuki ;

Yoshioka, Hiroshige ;

Takeshita, Jumpei ;

Tanaka, Kosuke ;

Nanjo, Shigeki ;

Fujita, Shiro ;

Kaji, Reiko ;

Imai, Yukihiro ;

Monden, Kazuya ;

Matsumoto, Takeshi ;

Nagata, Kazuma ;

Otsuka, Kyoko ;

Tachikawa, Ryo ;

Tomii, Keisuke ;

Kunimasa, Kei ;

Iwasaku, Masahiro ;

Nishiyama, Akihiro ;

Ishida, Tadashi ;

Nishimura, Yoshihiro .

CANCER, 2013, 119 (24) :4325-4332

← 1 2 3 4 →